Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Globus Medical Inc (NYSE: GMED) was $84.28 for the day, down -3.55% from the previous closing price of $87.38. In other words, the price has decreased by -$3.55 from its previous closing price. On the day, 1.11 million shares were traded. GMED stock price reached its highest trading level at $87.015 during the session, while it also had its lowest trading level at $84.25.
Ratios:
Our analysis of GMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.02.
On December 02, 2024, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $83 to $100.
Wells Fargo Upgraded its Equal Weight to Overweight on August 07, 2024, whereas the target price for the stock was revised from $60 to $78.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 10 ’25 when Pfeil Keith W sold 14,167 shares for $88.29 per share. The transaction valued at 1,250,770 led to the insider holds 0 shares of the business.
Pfeil Keith W bought 14,167 shares of GMED for $1,250,772 on Jan 10 ’25. On Dec 02 ’24, another insider, Huller Kelly, who serves as the SVP, GC, Corporate Secretary of the company, sold 2,500 shares for $87.00 each. As a result, the insider received 217,502 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 11476155392 and an Enterprise Value of 11317779456. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 127.14, and their Forward P/E ratio for the next fiscal year is 24.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.63 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 4.566 whereas that against EBITDA is 17.359.
Stock Price History:
The Beta on a monthly basis for GMED is 1.17, which has changed by 0.65649295 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $49.33. The 50-Day Moving Average of the stock is -2.63%, while the 200-Day Moving Average is calculated to be 13.84%.
Shares Statistics:
GMED traded an average of 1.08M shares per day over the past three months and 1331250 shares per day over the past ten days. A total of 113.47M shares are outstanding, with a floating share count of 112.12M. Insiders hold about 17.66% of the company’s shares, while institutions hold 79.80% stake in the company. Shares short for GMED as of 1738281600 were 2180970 with a Short Ratio of 2.31, compared to 1735603200 on 2489401. Therefore, it implies a Short% of Shares Outstanding of 2180970 and a Short% of Float of 2.15.
